TG THERAPEUTICS, INC.
TGTX · Nasdaq · United States
Share price · TGTX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when TGTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026+5.4%
- 30 Oct 2026+5.3%
Nothing announced by TGTX that day or the session before.
- 16 Sep 2026+5.3%
Nothing announced by TGTX that day or the session before.
- 21 Aug 2026+7.3%
Nothing announced by TGTX that day or the session before.
- 3 Aug 2026-11.3%
- 10 Jun 2026+7.5%
- 3 Jun 2026+9.5%
- 6 May 2026+16.3%
- 22 Apr 2026+5.6%
Nothing announced by TGTX that day or the session before.
- 20 Apr 2026+4.6%
Nothing announced by TGTX that day or the session before.
Share of unusual movement by asset
For each asset, the share of TGTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
Ublituximab(Briumvi) | Approved | CD20Monoclonal antibody | Multiple SclerosisSchizophreniaMyasthenia Gravis |
| Phase 1 | CD19Cell therapy | Multiple SclerosisDiffuse Large B-Cell Lymphoma Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
2028 (2)
2030 (1)
January 2030 (1)
What to watch
2032 (1)
May 2032 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $260M | $51M | $429M+ $75M short-term inv. | —$45M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $240M | $95M | $483M+ $70M short-term inv. | —$39M operating cash flow | report ↗ |
| 2026-Q1 | $205M | $48M | $442M+ $72M short-term inv. | —-$18M operating cash flow | report ↗ |
| 2025-Q3 | $162M | $41M | $74M+ $58M short-term inv. | —-$23M operating cash flow | report ↗ |
| 2025-Q2 | $141M | $32M | $129M+ $123M short-term inv. | —$7.4M operating cash flow | report ↗ |
| 2025-Q1 | $121M | $46M | $132M+ $144M short-term inv. | —-$29M operating cash flow | report ↗ |
| 2024-Q3 | $84M | $20M | $196M+ $145M short-term inv. | —-$12M operating cash flow | report ↗ |
| 2024-Q2 | $73M | $18M | $83M+ $134M short-term inv. | —$5.5M operating cash flow | report ↗ |
| 2024-Q1 | $63M | $33M | $75M+ $134M short-term inv. | $11M-$8.2M operating cash flow | report ↗ |
| 2023-Q3 | $166M | $15M | $151M+ $78M short-term inv. | —$84M operating cash flow | report ↗ |
| 2023-Q2 | $16M | $28M | $97M+ $48M short-term inv. | $48M-$42M operating cash flow | report ↗ |
| 2023-Q1 | $7.8M | $16M | $61M+ $78M short-term inv. | $39M-$60M operating cash flow | report ↗ |
| 2022-Q3 | $0.1M | $21M | $110M+ $66M short-term inv. | $36M-$34M operating cash flow | report ↗ |
| 2022-Q2 | $0.6M | $27M | $147M+ $49M short-term inv. | $41M-$49M operating cash flow | report ↗ |
| 2022-Q1 | $2.0M | $48M | $186M+ $48M short-term inv. | $69M-$69M operating cash flow | report ↗ |
| 2021-Q3 | — | $52M | $327M+ $30M short-term inv. | —-$67M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $616M | $160M | $79M+ $63M short-term inv. | —-$25M operating cash flow | report ↗ |
TG THERAPEUTICS, INC. reported revenue of $616.29M, up 87.3% YoY, R&D spend of $160.22M, up 69.9% YoY, cash and equivalents of $79.15M, and net income of $447.18M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $329M | $94M | $180M+ $131M short-term inv. | —-$41M operating cash flow | report ↗ |
| 2023-FY | $234M | $76M | $93M+ $125M short-term inv. | —-$31M operating cash flow | report ↗ |
| 2022-FY | $2.8M | $125M | $102M+ $59M short-term inv. | $50M-$176M operating cash flow | report ↗ |
| 2021-FY | $6.7M | $223M | $299M+ $16M short-term inv. | $87M-$296M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 2 sales ($438K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-10 | Charney Laurence N · director | Open-market sale | 5,000 | $54.96 | $275K | Form 4 |
| 2026-08-07 | Charney Laurence N · director | Gift | 500 | — | — | Form 4 |
| 2026-08-07 | Charney Laurence N · director | Gift | 450 | — | — | Form 4 |
| 2026-08-06 | Charney Laurence N · director | Gift | 5,100 | — | — | Form 4 |
| 2026-06-11 | Charney Laurence N · director | Award / grant (derivative) | 8,325 | — | — | Form 4 |
| 2026-06-11 | Echelard Yann · director | Award / grant (derivative) | 8,325 | — | — | Form 4 |
| 2026-06-11 | Hoberman Kenneth · director | Award / grant (derivative) | 8,325 | — | — | Form 4 |
| 2026-06-11 | HUME DANIEL · director | Award / grant (derivative) | 8,325 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 356 reporting institutions held 105.4M shares ($3.4B).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 22,252,930 | $739.2M |
| 2 | STATE STREET CORP | 8,649,766 | $287.3M |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 8,273,979 | $274.9M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 6,603,258 | $219.4M |
| 5 | Soleus Capital Management, L.P. | 4,029,319 | $133.9M |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 3,499,916 | $116.3M |
| 7 | Clearbridge Investments, LLC | 3,210,930 | $106.7M |
| 8 | GOLDMAN SACHS GROUP INC | 2,287,688 | $76.0M |
| 9 | CONGRESS ASSET MANAGEMENT CO | 2,168,081 | $72.0M |
| 10 | JANE STREET GROUP, LLC | 2,041,669 | $67.8M |
| 11 | CITADEL ADVISORS LLC | 1,922,889 | $63.9M |
| 12 | Pictet Asset Management Holding SA | 1,747,373 | $58.0M |
| 13 | Hood River Capital Management LLC | 1,569,171 | $52.1M |
| 14 | TWO SIGMA INVESTMENTS, LP | 1,542,312 | $51.2M |
| 15 | BANK OF AMERICA CORP /DE/ | 1,461,302 | $48.5M |